Bayer’s 'Adempas tab,' a treatment for chronic thromboembolic pulmonary hypertension (CTEPH), is being considered for reimbursement listing 10 years after its approval as a novel drug.

According to industry sources on July 2nd, a reimbursement decision application for Adempas was recently submitted to the Health Insurance Review and Assessment Service (HIRA).

This drug obtained approval in South Korea as an orphan drug in June 2014. Five products with different doses are available, and it has the efficacy and the effect in ▲patients with persistent/recurrent chronic-thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) after surgical treatment or inoperable CTEPH, to improve exe